DOCSLIB.ORG

2017-Mt-Sinai-Prospectus Alt.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2017-Mt-Sinai-Prospectus Alt.Pdf Dear Industry Colleagues: Course Director On behalf of Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in Ash Tewari, MBBS, MCh New York City, I would like to invite you to partner with the Second International Prostate Co –Directors Cancer Symposium and Inaugural World Congress of Robotic Oncology being held on Ketan K. Badani, MD September 6-9, 2017 at Mount Sinai Hospital in New York, New York. Ranked among the Nina Bhardwaj, MD, PhD nation’s best for Urology in the 2016-2017 "Best Hospitals" issue of U.S. News & World Carlos Cordon-Cardo, MD, PhD Report, the physicians of Mount Sinai Urology Associates are leaders in robotic surgery and William Oh, MD minimally invasive procedures to treat prostate, kidney, and bladder cancers. The Mount Sinai Site Directors Urology team is also on the forefront of diagnosis and treatment for urinary tract and prostate Mantu Gupta, MD disorders, erectile dysfunction, kidney stones, infertility, and pediatric urologic conditions. Michael A. Palese, MD Join the Mount Sinai Department of Urology for an interactive symposium with 3D demonstration of the latest robotic surgery techniques for prostate, kidney and bladder cancer. Directed by the world’s leading robotic experts and taught by an internationally renowned faculty, attendees gain emerging and practical tools to optimize their robotic surgical skills. Highlights include 3D viewing of robotic surgeries including prostate, kidney, bladder and reconstruction, point-counterpoint debates and inaugural address by Dennis Charney, MD, Dean of the Icahn School of Medicine at Mount Sinai. Affiliating with the Second International Prostate Cancer Symposium and Inaugural World Congress of Robotic Oncology is the most direct route in meeting with and sharing your products with some of the most well-known and respected health care providers and decision makers in the urological community. As an essential part of the symposium, you will be able to place your product in the hands of key opinion leaders in the field and encourage new and existing relationships. Please review the 2017 Partnership Prospectus and reserve your prime exhibit space today to participate in this cutting-edge urologic oncology conference. We look forward to having you as our industry partner. More information can be found at Mountsinaiurologycme.org or if you have questions please call Christina Espiritu at (847)892-7641 or via email at [email protected]. Sincerely, Christina C. Espiritu Director of Specialty Programs Veritas Meeting Solutions | 2575 Northwest Parkway | Elgin, Illinois 60124 W: (847)892-7641 | F: (224)888-2661 | [email protected] Mountsinaiurologycme.org PARTNERSHIP INFORMATION GENERAL INFORMATION Payment is due no later than August 1, 2017 The World Congress of Robotic Oncology will provide attendees with Continuing Medical Education (CME) in Cancellations & Refunds: addition to advanced knowledge with a multi-disciplinary Our administrative office requires that all cancellations must robotics surgical focus, combined with new product be in writing. The following refund schedule applies: knowledge learned in the exhibit hall. • Cancellation on or prior to August 1, 2017, your exhibit fee will be refunded less a $250 administration fee. Official Meeting Dates: September 6-9, 2017 • Cancellation after August 1, 2017; no portion of the Official Exhibit Dates: September 6-9, 2017 original exhibit fee will be refunded. MEETING LOCATION Assignment of Space: The Mount Sinai Hospital Exhibit space will be assigned at the sole discretion of the 1 Gustave L. Levy Place Congress. Factors affecting exhibit location include support New York, NY 10029-6574 level; the sign-up and payment date of the application, the number of exhibits, and proximity of competitors. SUPPORTING MOUNT SINAI UROLOGY EXHIBIT SCHEDULE Deliver your message in a professional, focused, and The schedule below is for companies that will be educational environment. The World Congress of Robotic participating at this meeting. Oncology provides you with networking opportunities to Times are subject to change without notice build relationships with new and existing customers. Choose a standard exhibit booth or a promotional partnership Exhibit Set-Up: package, which provides extended promotional visibility for Wednesday, September 6, 2017 8:00am – 12:00pm your company beyond the annual meeting. Exhibit Hours: Wednesday, September 6, 2017 1:00pm – 5:00pm EXHIBITING Thursday, September 7, 2017 6:30am – 5:30pm The expected 100 attendees want to meet you face-to-face Friday, September 8, 2017 6:30am – 4:00pm and examine your products first-hand. By exhibiting at the Saturday, September 9, 2017 6:30am – 6:00pm meeting, your company will be listed in promotional Exhibit Teardown: materials and the onsite program book. Space is limited, so Saturday, September 9, 2017 After 6:00pm act quickly! Registration: PROMOTIONAL PARTNERSHIP PACKAGES Only employees of the exhibiting company, or its agents, will Secure a prime exhibit location and optimum visibility with a be issued a badge. Booths must be manned the entire time the Pinnacle, Platinum, Gold, Silver, or Bronze Level Partnership exhibit area is open. package. In addition to your exhibit, participation in this program includes the pre-attendee registration list, your company logo and recognition in the annual meeting program For more information about exhibits, sponsorships, book, signage and more. Please refer to the Promotional or advertising opportunities to support the Second Partnership details in this prospectus for a complete list of International Prostate Cancer Symposium and Inaugural benefits. World Congress of Robotic Oncology through an educational grant, please contact: Exhibit Description: One 6-foot table with two chairs and a wastebasket. Christina C. Espiritu Additional service information will be made available Director of Specialty Programs approximately three to four weeks prior to the meeting. Veritas Meeting Solutions 2575 Northwest Parkway; Elgin, Illinois 60124 W: (847)892-7641 F: (224)888-2661 [email protected] Mountsinaiurologycme.org Pinnacle Platinum Gold Silver Bronze Exhibit SECOND INTERNATIONAL PROSTATE CANCER SYMPOSIUM Level Level Level Level Level Only AND INAUGURAL WORLD CONGRESS OF ROBOTIC ONCOLOGY $50,000 $40,000 $30,000 $20,000 $10,000 $5,000 Promotional Partnership Benefits – Listed below are the benefits associated with each level Please select your level of support by indicating the amount in this row Full Page Black & White Ad in the Exhibit Guide INCLUDED INCLUDED Half-Page Black & White Ad in the Exhibit Guide INCLUDED INCLUDED INCLUDED INCLUDED Opportunity to host a Full-Day Program (Hands-On) during the INCLUDED meeting. (Meeting Room and Basic A/V included) TICKETS Six Complimentary Registrations INCLUDED INCLUDED Four Complimentary Registrations INCLUDED Two Complimentary Registrations INCLUDED INCLUDED ADVERTISEMENTS and MAILINGS One-Time Use of Attendee Mailing Labels INCLUDED INCLUDED INCLUDED INCLUDED (piece must be pre-approved by administrative office) Pre-Registration Attendee List INCLUDED INCLUDED INCLUDED INCLUDED Post Meeting Attendee List INCLUDED INCLUDED INCLUDED INCLUDED INCLUDED INCLUDED RECOGNITION Company Logo Displayed on the Website INCLUDED INCLUDED INCLUDED INCLUDED INCLUDED Company Logo Displayed on Signage INCLUDED INCLUDED INCLUDED INCLUDED INCLUDED Company Logo Displayed in the Newsletter INCLUDED INCLUDED INCLUDED INCLUDED INCLUDED Company Signage Recognized on the Website INCLUDED INCLUDED INCLUDED INCLUDED Company Sponsorship Recognized on Signage INCLUDED INCLUDED INCLUDED INCLUDED Company Sponsorship Recognized in Exhibit Guide INCLUDED INCLUDED INCLUDED INCLUDED EXHIBITING & BADGES Prime Booth - Unlimited Exhibit Attendee Badges INCLUDED INCLUDED Featured Booth - 6 Exhibit Badges INCLUDED Standard Booth - 4 Exhibit Badges INCLUDED INCLUDED INCLUDED ADDITIONAL EVENT TICKETS Welcome Reception with each Exhibit Attendee Badge INCLUDED INCLUDED INCLUDED INCLUDED INCLUDED INCLUDED ADDITIONAL ADVERTISING AND SPONSORSHIP OPPORTUNITIES Opportunity Description Please select your opportunities by Cost (See Guidelines Page for Further Details) marking the amount below Industry Sponsored Speaker Presentation $25,000 Poster Pavilion Sponsorship (Exclusive) $25,000 (Company Logo Displayed on GOBO) Wireless Code for Meeting Space (Exclusive) $25,000 (Company Logo and Code Displayed on GOBO in Meeting Space) Partial Sponsorship of the Welcome Reception in the Exhibit Hall $25,000 (Company Logo Displayed on GOBO During Reception) Full Color Ad on Back Cover or Inside Front Cover of the Exhibit Guide $10,000 (Location selection on a first come-first served basis) Company Logo with Welcome Message on GOBO in Featured Location in Meeting Space $10,000 Schedule-At-A-Glance Sponsorship $7,500 Attendee Arrival Bags Distributed at Registration (Exclusive) $7,500 Full Page Black & White Ad in the Exhibit Guide $5,000 Half-Page Black & White Ad in the Exhibit Guide $2,500 TOTAL Sponsorship Level (From Top Table) TOTAL from Additional Advertising and Sponsorship Opportunities (From This Table) GRAND TOTAL of SPONSORSHIP ADVERTISING & DIGITAL SUBMISSION GUIDELINES Full Page Advertisement in Exhibit Guide – This advertisement should be in portrait orientation. The specifications for the advertisement are 8.5” wide x 11” high with a ¼” bleed. The image should be black and white and should be sent in a high-resolution PDF format. Deadline is
Load more

Recommended publications
  • Prospectus Symp19-8-2019.Indd
    EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS TH INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM NOVEMBER 7-9, 2019 NEW YORK, NY MOUNTSINAIUROLOGYCME.ORG HIGHLIGHTS • Over 100 world-renowned faculty • Engaging point-counterpoint debates and • Live 3-D surgical demonstrations, including panel discussion prostate, kidney, bladder procedures • Global exposure with international web streaming of select sessions and events Welcome to the Fourth International Prostate Cancer and Urologic Oncology Symposium. EDUCATIONAL HIGHLIGHTS • Live 3-D surgery transmission covering complex urologic surgery • Comprehensive didactic lectures from the world’s leading experts in urologic oncology • Robust review of the latest advances in surgical techniques and management of prostate, kidney, and bladder cancer • Personal interaction with world-class faculty • Stimulating point-counterpoint debates on timely topics DAILY HIGHLIGHTS PROSTATE DAY 1 THUR. 11/7/19 PROSTATE DAY 2 FRI. 11/8/19 KIDNEY & BLADDER SAT. 11/9/19 • Advanced imaging in genomics • Innovations in the management of • New progress in pre-operative and for prostate cancer castrate-sensitive prostate cancer intra-operative imaging, 3-D • Biomarkers and immunotherapy modelling, and ultra sound • Focus on radiomics and guidance for renal tumors radiogenomics • Update on clinical trials for castrate-resistant treatments for • Novel therapeutics in the • Utility of imaging and artificial prostate cancer management of metastatic renal intelligence in prostate cancer cell carcinomas:
    [Show full text]
  • In the News September 30, 2016
    From: ITNDaily on behalf of Werle, Laura Subject: Mount Sinai In the News - September 30, 2016 Date: Friday, September 30, 2016 2:06:09 PM Attachments: ATT00002.txt In the News September 30, 2016 Nature – September 30 Inflammation in Patients With Cushing Disease — Claire Greenhill Circulating levels of proinflammatory cytokines are increased in patients with Cushing disease, both during active disease and after remission, according to new data published in Clinical Endocrinology. These findings demonstrate that cytokine levels are increased in patients after remission of Cushing disease, which could explain the persistent increased risk of cardiovascular-related death. The study, led by Eliza Geer, MD, a professor of endocrinology at the Icahn School of Medicine at Mount Sinai, notes that more studies are needed to determine why levels of IL-6 and IL-1β remain elevated after remission of Cushing disease. - Eliza Geer, MD, Associate Professor, Medicine, Endocrinology, Diabetes and Bone Disease, Neurosurgery, Icahn School of Medicine at Mount Sinai Learn more: http://www.nature.com/nrendo/journal/vaop/ncurrent/full/nrendo.2016.170.html WCBS – September 29 ‘Artificial Pancreas’ Expected To Make Life Easier, Healthier For Type 1 Diabetes Patients — Max Gomez A groundbreaking new device could change the lives of millions of people living with diabetes. Federal regulators just approved an artificial pancreas that can monitor and administer insulin. The key is a computer algorithm that does those calculations faster and more accurately than a patient can. “It looks at the numbers from a moment to moment basis, and it will proactively predict what is going to happen next and make clinical decisions that cannot be done at that rate.
    [Show full text]
  • In the News July 29, 2016
    From: ITNDaily on behalf of Stephanie Sherman Subject: Mount Sinai In The News - July 29, 2016 Date: Friday, July 29, 2016 11:20:39 AM Attachments: ATT00002.txt In the News July 29, 2016 WBUR News – July 28 Doctors Need A New Skill Set For This Opioid Abuse Treatment — Karen Shakerdge Braeburn Pharmaceuticals, the company behind the newly FDA-approved treatment Probuphine, is teaching doctors how to use it. Although addiction specialists welcome Probuphine, which delivers a constant dose of the drug buprenorphine over six months, at this early stage it's complicated for physicians to add it to their repertoire. Patients using Probuphine were 14 percent more likely to stay opioid-free compared to those using a daily sublingual version of buprenophine, according to a study published this month in JAMA, the Journal of the American Medical Association. So it's good to have another way to deliver medication-assisted treatment, says Richard Rosenthal, medical director of addiction psychiatry for the Mount Sinai Health System. Rosenthal was one of two principal investigators on a Probuphine clinical trial. "Everybody is waking up to the fact that we're in the midst of an opioid epidemic," says Rosenthal. "There are actually very few medications for addiction of any kind. Given the addiction treatment system in the United States, most of the treatment that's given is psychosocial. There's very little use of FDA-approved medications." - Richard N. Rosenthal. MD, Professor, Psychiatry, Mount Sinai West Learn more: http://www.wbur.org/npr/487080738/doctors-need-a-new-skill-set-for-this-opioid-abuse- treatment MD Alert – July 28 Some Non-Celiac Gluten Sensitivity Patients May Have 'Celiac Lite' Disease — Marilynn Larkin A subset of patients with non-celiac gluten sensitivity (NCGS) may actually have a form of celiac disease, researchers in Spain report.
    [Show full text]
  • PARTNERSHIP PROSPECTUS SEPTEMBER MOUNT SINAI HOSPITAL 7-9 NEW YORK, NEW YORK 2017 Second International Urologic Cancer Symposium
    EXHIBITOR AND PROMOTIONAL PARTNERSHIP PROSPECTUS SEPTEMBER MOUNT SINAI HOSPITAL 7-9 NEW YORK, NEW YORK 2017 Second International Urologic Cancer Symposium HIGHLIGHTS • Over 80 renowned global faculty • Live 3D surgical demonstrations, including prostate, kidney, bladder and reconstruction • Point-Counterpoint Debate • Annual Push Up Challenge • Gala to Raise Funds for Urologic Cancer Research TOPIC AREAS • Screening and Low Risk Disease • Localized Prostate Cancer • Biomarkers and Genomics • Advanced Prostate Cancer • Immunotherapy • Kidney Cancer • Focal Therapy • Bladder Cancer www.mountsinaiurologycme.org TABLE OFCONTENTS Invitation to Exhibit/Sponsor . 1 Department of Urology 75th Anniversary Session . 2 Screening & Low Risk Disease . 3 Focal Therapy . 4 Treatment Failure . 4 Immunotherapy & Tumor Microenvironment . 5 Radical Prostatectomy . 6 Treating Localized Disease . 7 Advanced Prostate Cancer . 8 Locally Advance Disease. 9 Quality of Life . 9 Kidney Cancer - I. 10 Kidney Cancer - II . 11 Kidney Cancer - III . 12 Bladder Cancer I . 13 Partnership Information . 14 Partnership Opportunities . 15 Exhibit Registration Form . 17 Agenda. 18 Invitation to Exhibit/Sponsor 1 Course Director Dear Industry Colleagues: Ash Tewari, MBBS, MCh On behalf of the Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in New York City, I Co –Directors would like to invite you to partner with the 2nd International Urologic Cancer Symposium being held on September On behalf of the Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in New Ketan K. Badani, MD 6-9, 2017 at the Mount Sinai School of Medicine in New York, NY. Ranked among the nation’s best for Urology York City, I would like to invite you to partner with the Second International Prostate Cancer Nina Bhardwaj, MD, PhD in the 2016-2017 "Best Hospitals" issue of U.S.
    [Show full text]
  • Curriculum Vitae [PDF]
    CURRICULUM VITAE GYAN PAREEK, M.D. Academic Address: 2 Dudley Street, Suite 174 Providence, RI 02905 Academic Telephone Number: 401-444-8570 Academic Fax Number: 401-444-6947 Mobile Number: 401-537-7763 Electronic Mail Address: [email protected] EDUCATION Undergraduate: University of Pittsburgh, Pittsburgh, PA Bachelor of Science in Neuroscience, 1991 Graduate: Roswell Park Cancer Institute, SUNY at Buffalo Buffalo, NY Master of Science, 1993 Brown University Providence, RI Master of Arts ad eundem, 2014 Harvard Medical School Boston, MA 2018-Current Harvard Certificate in Leadership Medical School: St. George’s University School of Medicine, M.D., 1998 POSTGRADUATE TRAINING Residency: Lenox Hill Hospital, New York, NY Surgery (PGY1), 7/1/1998-6/30/1999 Lenox Hill Hospital, New York, NY Surgery (PGY2), 7/1/1999-6/2000 Lenox Hill Hospital, New York, NY Urology, 7/1/2000-6/30/2004 Fellowship: Laparoscopy and Endourology, University of Wisconsin, Madison, WI Clinical Instructor, 7/1/2004-6/30/2005 1 POSTGRADUATE HONORS AND AWARDS 2004 American Urological Association Pfizer Scholar 2005 Annual Essay Contest, Second Place, “Basic Science” and “Elastographic Measurements of In-Vivo Radiofrequency Ablation Lesions of the Kidney.” Endourological Society, Amsterdam, Netherlands 2006 Urology (Gold Journal) Essay Contest, Second Place, “Shockwave Lithotripsy Success Based on Skin to Stone Distance on Computed Tomography.” American Urological Association, Atlanta, Georgia 2009 The Dean’s Excellence in Teaching Award, “Urology Clinical Elective”,
    [Show full text]
  • 2018 Star Reviewers for Urologic Oncology
    Urologic Oncology: Seminars and Original Investigations 37 (2019) 229−262 2018 Star Reviewers for Urologic Oncology While the value of any medical journal depends upon the Sabine Brookman-May, Ph.D., M.D. quality of manuscripts received, the backbone of a journal’s LMU Munich, Dept. of Urology, Munich, Germany success is created by those who review manuscripts, iden- Clint Cary, M.D., M.P.H. tify problematic issues, make critical suggestions for Urology, Indiana University School of Medicine, Indianapolis, improvement, and assist the journal’s editors in deciding on Indiana, United States a manuscript’s disposition. This is no small task, and all too Edmund Chiong, M.B.B.S., Ph.D., F.R.C.S.Ed, F.R.C.S.I, F.A.M.S often it may feel thankless. Urology, National University Health System, Singapore, Singapore By acknowledging those reviewers whom our editors Nicholas Cost, M.D. have identified as “Star Reviewers,” Urologic Oncology Department of Surgery, Division of Urology, University of seeks to underscore the outstanding work that these Colorado School of Medicine, Aurora, CO, United States reviewers have done for the Journal over the course of this Chendil Damodaran, Ph.D. past year. We also wish to identify and thank all reviewers Urology, Univiersity of Louisville, Louisville, KY, United States for their excellent work and contributions in 2018. The Alexander Glaser, M.D. April 2019 issue of Urologic Oncology will therefore con- Department of Urology, Northwestern University, Chicago, IL, tinue its tradition of recognizing its reviewers such that all United States of our 2018 Reviewers and the Editors’ “Star Reviewers” Michael Gorin, M.D.
    [Show full text]
  • In the News June 1, 2018
    From: ITNDaily Subject: Mount Sinai In The News - June 1, 2018 Date: Friday, June 01, 2018 1:51:23 PM Attachments: ATT00001.txt In the News June 1, 2018 Core77 – May 31 A Clinic And Research Lab Designed To Make The Patient Experience Pleasant and Comprehensive — Emily Engle Medical spaces need a facelift, from furnishing to digital screens to the entire patient experience. This past year, Cactus team worked closely with the Mount Sinai Health System to develop Lab100, a new type of medical environment that focuses on the different ways in which developing technologies can improve how we understand and experience medical attention and healthcare. Lab100 equips scientists with longitudinal multi-scale health data and a testbed environment to develop, validate and deploy new products and services. By closing the feedback loop between discovery science and care delivery, Lab100 creates a virtuous cycle of innovation that radically accelerates the pace at which promising ideas become clinical practice. - David Stark, MD, Assistant Professor, Health System Design and Global Health, Icahn School of Medicine at Mount Sinai, Medical Director, Institute for Next Generation Health Care Learn more: http://www.core77.com/posts/77952/A-Clinic-and-Research-Lab-Designed-to-Make-the-Patient-Experience-Pleasant-and-Comprehensible International Business Times – June 1 Mount Sinai And RenalytixAI Launch Groundbreaking Artificial Intelligence Solution For Improved Kidney Disease Management and Patient Care Mount Sinai Health System and RenalytixAI, Plc today have entered into an exclusive multi-year license and collaboration to commercialize artificial intelligence solutions to improve kidney disease detection, management and treatment for patients with diabetes and other at-risk, large-scale patient populations.
    [Show full text]
  • Curriculum Vitae
    Benjamin R. Lee, M.D. CURRICULUM VITAE Name Benjamin R. Lee, M.D. Present Position Professor and Chief of Urology with tenure University of Arizona College of Medicine Program Director, Urology Residency Present Location Division of Urology Arizona Health Sciences Center 1501 N. Campbell Ave., PO Box 245077 Tucson, AZ 85724-5077 (520) 626-6895 (Phone) (520) 626-4933 (FAX) Email Address [email protected] Education 1986-1990 Bachelor of Arts, Biological Sciences, Magna Cum Laude College of Arts and Sciences Cornell University, Ithaca, New York Senior Honors Thesis: Binding Studies of cell surface Immunoglobulin E- receptor complexes 1990-1994 M.D., Doctor of Medicine The Johns Hopkins School of Medicine Baltimore, Maryland Page 1 of 76 Benjamin R. Lee, M.D. Training / Education / Position General Surgery Internship 1994-95 The Johns Hopkins Hospital General Surgery Resident 1995-96 The Johns Hopkins Hospital Urology Resident 1996-00 The James Buchanan Brady Urological Institute The Johns Hopkins Hospital Assistant Chief Of Service (ACS) 2000-01 The Johns Hopkins Hospital Assistant Professor 2001-04 North Shore - Long Island Jewish Medical Center Albert Einstein College of Medicine Associate Professor 2004-08 North Shore - Long Island Jewish Medical Center Albert Einstein College of Medicine Director, Laparoscopy Section, Long Island Jewish Medical Center Professor (with tenure) 2008-16 Department of Urology Tulane University School of Medicine Director, Fellowship Program in Robotics, Laparoscopy & Endourology Professor 2010-16 Professor of Medicine, Section of Hematology-Oncology Tulane University School of Medicine Professor & Chief (with tenure) 2016-present Division of Urology Department of Surgery University of Arizona College of Medicine Director, GU Cancer & Disease Oriented Strategic Planning Team University of Arizona Cancer Center Program Director, Urology Residency Certification Diplomate, American Board of Urology, #13100, expires 2/28/2023 DaVinci Robotic Training Certificate 2005 Page 2 of 76 Benjamin R.
    [Show full text]
  • The Urology Residency Program of the Icahn School of Medicine at Mount Sinai
    THE UROLOGY RESIDENCY PROGRAM OF THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Overview The Icahn School of Medicine at Mount Sinai Urology Residency Program is an ACGME-accredited program with a training format consisting of one year of preliminary training in general surgery followed by four years of urology. Its home institution is The Mount Sinai Hospital in New York City. The program is currently approved for a complement of five residents per training year. The program curriculum assures that over the course of training, every resident receives ample experience and didactic grounding in all of the core domains and techniques of urology while acquiring the professional skills and competencies that are characteristic of excellent physicians. Each of the 19 rotations that comprise the curriculum include experience in both in-patient and out-patient treatment settings, with selected rotations offering concentrated experience in areas such as pediatric urology, urodynamics, endourology, female urology, infertility and oncology. An overarching schedule of conferences (led by faculty, fellow residents and guest lecturers), collaborative research projects and support for participation in professional organizations and special programs knit the residents’ clinical experience into the fabric of current urologic scholarship. Our home and affiliated institutions offer an immersive experience in three distinct health care delivery models: the tertiary care academic medical center, the community hospital and the municipal hospital system. Our graduates finish the program with an enviable understanding of the options that are open to them, and well equipped to pursue the urology careers of their choosing. Home and Affiliated Institutions The Mount Sinai Health System consists of seven hospital campuses, each of them a venerable New York institution, located in Manhattan, Brooklyn and Queens.
    [Show full text]
  • 2017 Annual Meeting
    PRELIMINARY PROGRAM Register at cns.org/2017 Advance Registration Deadline: September 7, 2017 2017 CNS2017 ANNUAL MEETING PRELIMINARY PROGRAM TION CELE ORMA BRAT NSF ION TRA CONGRESS OF NEUROLOGICAL SURGEONS 2017 ANNUAL MEETING BOSTON, MASSACHUSETTS # OCTOBER 7–11, 2017 PRESIDENT’S MESSAGE Change is inevitable. In the moments that pass as you read this, mountains erode, plants and animals adapt, and stars dim—all in imperceptibly slow motion. In a similar way, our profession changes. As our knowledge grows exponentially and technology accelerates, we must also adapt and transform into what is possible. Essentially, this has been the core of every CNS Annual Meeting for the past 67 years—to assess our reality, anticipate a better future, point our collective energies in the direction of that future, and prepare for the change we must create. Simultaneously, it is also important to note all that we have accomplished. Neurosurgery can proudly say that what was lethal only a few generations ago, is now survivable. Our ongoing achievements deserve our admiration and are cause for celebration. This paradox between all we have done and all that we have left to do is what drives us to become better. It is also the driving concept behind this year’s CNS Annual Meeting theme Transformation and Celebration. Within this Preliminary Program, you will see dozens of educational programs and sessions containing both today’s state-of-the-art neurosurgery and insight into how neurosurgery is changing. You will find some courses that look familiar and some that are completely new. Some formats that were once didactic and lecture-driven have been transformed into interactive and hands-on.
    [Show full text]
  • Symposium 2018 V2-For Emailing.Indd
    December 13-15, 2018 The Mount Sinai Hospital 1 Gustave L. Levy Place New York, NY In collaboration with Society of Urologic Robotic Surgeons and Endourological Society DIRECTOR: Dear Medical Colleagues: Ash Tewari, MBBS, MCH Professor and Chairman of the Department of Urology On behalf of the Department of Urology at the Icahn School of Medicine at Department of Urology Mount Sinai in New York City, I am thrilled to invite you to participate in the [email protected] Third International Prostate Cancer and Urologic Oncology Symposium set for CO-DIRECTOR: December 13-15, 2018 in New York! This year’s program is our most innovative yet, Ketan Badani, MD complete with over 100 world-renowned experts who will provide in-depth Professor of Urology and Vice Chairman of the training on cutting-edge medical advances and ground-breaking treatment Department of Urology Department of Urology approaches for prostate, kidney, bladder, and renal cell cancers. [email protected] PLANNING COMMITTEE: Nina Bhardwaj, MD, PhD SYMPOSIUM TOPICS Professor of Medicine, Hematology, n and Medical Oncology Epidemiology and Early Diagnosis of Prostate Cancer Department of Medicine, Hematology, and n Staging, Imaging, and Genomics Medical Oncology n [email protected] Management of Very Low Risk and Low Risk Prostate Cancer n Focal Therapy Carlos Cordon-Cardo, MD, PhD n Professor and Chairman of the Department of Surgical Treatment of Intermediate Risk Prostate Cancer Pathology n Sexual Health Following Prostatectomy Department of Pathology [email protected]
    [Show full text]
  • International Prostate Cancer and Urologic Oncology Symposium
    EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS 2018 RD 3 INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM DECEMBER 13-15, 2018 NEW YORK, NY MOUNTSINAIUROLOGYCME.ORG HIGHLIGHTS • Over 100 world-renowned faculty • Engaging point-counterpoint debates and • Live 3D surgical demonstrations, including panel discussion prostate, kidney, bladder procedures • Global exposure with international web streaming of select sessions and events TOPIC AREAS • Epidemiology and Early Diagnosis of Prostate Cancer • Staging, Imaging, and Genomics • Management of Very Low Risk and Low Risk Prostate Cancer • Focal Therapy • Surgical Treatment of Intermediate Risk Prostate Cancer • Sexual Health Following Prostatectomy • Radical Prostatectomy • Immunotherapy and Tumor Microenvironment • Upper Tract Disease • Partial Nephrectomy • Kidney Cancer • Bladder Cancer • PARP Inhibitors in Prostate Cancer DECEMBER 13 – 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS DIRECTOR: ASH TEWARI, MBBS MCH Professor and Chairman of the Department INVITATION of Urology Department of Urology TO EXHIBIT/SPONSOR [email protected] CO-DIRECTOR: Dear Industry Colleagues: KETAN BADANI MD Professor of Urology and Vice Chairman of the Department of Urology On behalf of the Department of Urology at the Icahn School of Medicine at Department of Urology Mount Sinai in New York City, I am thrilled to invite you to participate in the Third [email protected] International Prostate Cancer and Urologic Oncology Symposium set for December 13-15, 2018 in New York! This year’s program is our most innovative yet, complete PLANNING COMMITTEE: with over 100 world-renowned experts who will provide in-depth training on cutting- NINA BHARDWAJ MD, PhD edge medical advances and ground-breaking treatment approaches for prostate, Professor of Medicine, Hematology, kidney, bladder, and renal cell cancers.
    [Show full text]